Nevertheless, one above-mentioned study which indicated increased CSF glutamine levels examined patients with probable AD only positive for the biomarker amyloid tau index (IATI) (thus showing clear evidence of both amyloid-β and tau neuropathology). This evidence concerns the gene MAPT and Alzheimer disease.